Supplemental figure 1 : Analysis of the efficiency of galectin-3 siRNA transfection. A, Knockdown of galectin-3 by siRNA transfection in MDCK cells. Cells were transfected with either luciferase siRNA as a control or with galectin-3 siRNAs, and cell lysates from 3 day cultures (not shown) or 7 day cultures were processed for Western blot analyses for galectin-3 (upper panel) or -tubulin (lower panel). After transfection of the galectin-3 siRNA mix (second lane), galectin-3 expression was reduced by 80 % (mean value of three distinct experiments; the most representative Western blot is presented). In contrast, the transfection with another galectin-3 siRNA was unable to reduce galectin-3 expression (inefficient gal3siRNA, third lane). B and C, MDCK cells were transfected with the inefficient galectin-3 siRNA (ineff. gal3siRNA) and cultured in Matrigel for 5 days. No effect was observed in the localization of gp114, gp135 (B), E-cadherin, ZO-1, aPKC, ezrin, -tubulin (C). Nuclei were detected by Hoechst 33342 staining. Scale bars, 10m.
Supplemental figure 2 : Silencing of galectin-3 with another competent siRNA, « gal3 siRNA#2 », induces the same range of defects. A, Efficiency of galectin-3 knockdown by siRNA#2 transfection. Cells were transfected with either luciferase siRNA as a control or with galectin-3 siRNA#2 and cell lysates from 7 day cultures were processed for Western blot analyses for galectin-3 (upper panel) or -tubulin (lower panel). After transfection with the galectin-3 siRNA#2 (second lane), galectin-3 expression was markedly reduced (two separate experiments were performed; a representative Western blot is presented). B, C. Distribution of gp114 and gp135 (B) and of ezrin and -tubulin (C) in cells transfected with galectin-3 siRNA#2. Transfection with galectin-3 siRNA#2 also leads to abnormal cystogenesis in MDCK cells. D, E, Distribution of acetylated -tubulin in MDCK cysts (D) or in MDCK cells grown in monolayer (E) after transfection with galectin-3 siRNA#2. Reduction in galectin-3 by galectin-3 siRNA#2 triggers the formation of abnormal cilia. F, G, Distribution of centrin-2 in MDCK cells grown as monolayer (F) or cysts (G) after transfection with galectin-3 siRNA#2. Aberrant centrosome-like structures form after galectin-3 silencing. Scale bars, B, C, D, G 10m, E : lower magnifications 10m, higher magnification (inserts on the right side) 3m, F 10m.
Supplemental figure 3: Galectin-3 intracellular localization evolves during epithelial cell differentiation. Confocal analyses of galectin-3 distribution during cell differentiation in MDCK cell monolayer (A, a-f) or Matrigel cysts (B-D). In A, MDCK cells have been stained with antibody directed against galectin-3 (red), at different time points. After cell seeding (day 0-2), galectin-3 is located at the nucleus and / or in the cytosol (a-b). In postconfluent cells (day 3-4), galectin-3 is dramatically redistributed and locates in single punctuate structures (white arrows), either in the perinuclear area (c) or at the apical domain (d). In differentiated MDCK cells (day 5-7), galectin-3 is present in cytoplasmic vesicular structures; however, the strongest galectin-3 signal is detected at the apical plasma membrane, as previously described (Delacour et al., 2007) . Scale bars, 10m. B, MDCK cysts were grown in Matrigel for 5 days, and galectin-3 distribution has been studied after immunostaining (green) and confocal acquisition. In MDCK cysts, galectin-3-positive vesicular structures were detected either in the cytoplasm or at the apical plasma membrane (white arrowheads). C, double stainings for galectin-3 (red) with either acetylated -tubulin (C) or centrin-3 (D) (green) in day 5 cysts. Galectin-3-positive apical vesicular structures (white arrowheads) were also positive for both markers, demonstrating that galectin-3 is located at the basal bodies in cells of Matrigel MDCK cysts. B, C, D: scale bars, 10m.
Supplemental figure 4: Galectin-3 distribution in mouse collecting duct cells. A, mouse kidney sections were immunostained for galectin-3 and analysed by confocal microscopy. In collecting duct cells, galectin-3 is located in the nucleus, in the cytoplasm and at the apical plasma membrane. B, double immunostainings for acetylated -tubulin (green) and galectin-3 (red). C, double immunostainings for galectin-3 (green) and centrin-2 (red). Here, galectin-3 is present in the nucleus and at the apical plasma membrane. Galectin-3 is not detected in the axoneme of the primary cilium. However, it is detected at the basal body, together with centrin-2 (white arrowheads). In summary, in mouse collecting duct cells, the presence of galectin-3 in the primary cilium is restricted to the basal body.
Supplemental figure 5: Depletion of galectin-3 leads to centrosomal abnormalities in Matrigel MDCK cysts. Distribution of centrin-3 in day 5 MDCK cysts, after transfections of control siRNAs (Mock and ineff. gal3siRNA) or of galectin-3 siRNA (gal3siRNA). The inserts show high magnifications of the regions in white boxes. In controls, centrin-3 was detected as small structures at the apical plasma membranes facing the central lumen. After reduction of galectin-3, centrin-3-positive structures were more numerous and found throughout the cytoplasm (white arrowheads). Nuclei were detected with Hoechst 33342 staining. Scale bars, 10m.
